POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC. et al

Track this case

Case overview

Case Number:

3:15-cv-07658

Court:

New Jersey

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Michael A. Shipp

Firms

Companies

Government Agencies

Sectors & Industries:

June 15, 2023
PwC Must Face Valeant Investor Suit Over Missed 'Red Flags'

A New Jersey federal judge has ruled that PwC cannot escape a lawsuit brought by shareholders of Valeant Pharmaceuticals International Inc. because the auditor missed "red flags" that could have caught the pharmaceutical company's alleged market manipulation earlier.
December 22, 2022
PwC Pins Blame On Valeant In Securities Fraud Suit

PricewaterhouseCoopers fought back against a special master's refusal to recommend tossing a securities fraud claim brought by investors of the former Valeant Pharmaceuticals International Inc., arguing it is a victim of the fraud, too.
September 21, 2021
PwC Can't Shed City's Claim In Valeant Securities Suit

A New Jersey federal judge on Tuesday refused to free PricewaterhouseCoopers from the remainder of a long-running securities lawsuit brought by investors of the former Valeant Pharmaceuticals International Inc., reasoning that an Arizona city and its pension fund met the pleading requirements for its stock-drop claim.
February 12, 2021
Robbins Geller's Money Experts Clinch $1.2B Valeant Deal

The landmark $1.21 billion settlement for Valeant investors presented a tricky task of maximizing recovery without driving the financially embattled drug company into insolvency, prompting lead counsel Robbins Geller Rudman & Dowd LLP to heavily mine its in-house experts for help structuring the right deal.
February 02, 2021
Final OK On $1.2B Valeant Deal Earns Robbins Geller $157M

A New Jersey federal judge gave final approval on Monday to a $1.2 billion settlement of an investor action against Valeant Pharmaceuticals, landing lead counsel Robbins Geller Rudman & Dowd LLP a hefty payday.
December 16, 2019
Bausch Will Pay $1.2B To End Valeant-Era Stock Suit

Bausch Health Cos. Inc. said Monday it will pay $1.2 billion to resolve a proposed securities class action accusing its former leaders of fraudulently inflating its stock when the Canadian company was known as Valeant Pharmaceuticals International Inc.
August 15, 2019
Judge Says Bid To Nix Valeant Stock-Drop Suit Unnecessary

A New Jersey federal judge said Thursday that it would be "a waste of judicial resources" to consider Valeant Pharmaceuticals' bid to toss a complaint from an options brokerage that is part of a proposed consolidated class action alleging Valeant fraudulently inflated its stock price, after previously rejecting the brokerage's own escape move.
July 01, 2019
Valeant Investor Can't Duck Insider Trading Claims

A New Jersey federal judge rejected an investment company's bid Sunday to dismiss claims that it illegally dumped Valeant stock ahead of revelations about the drugmaker's supposed deceptive sales practices, saying the firm and its CEO can't rely on their continued ownership of stock to avoid the claims.
March 29, 2019
Valeant Wants Ex-NJ AG Knocked Off Stock-Drop Suit

Valeant Pharmaceuticals urged a federal judge handling multibillion-dollar securities litigation against the company on Friday to yank the special master duties of a former New Jersey attorney general because of his firm's ties with pending and past litigation involving Valeant.
November 20, 2018
Pension Fund Slams Firm's Bid To Shed Valeant Fraud Suit

An Arizona public pension fund shot back at a hedge fund management company seeking to escape a multibillion-dollar securities class action over Valeant Pharmaceuticals International Inc.'s massive stock drop, reminding a New Jersey federal court Monday that it already rejected their bid to duck insider trading allegations.

← Previous
1
2
Next →